Minghan Yong

Minghan Yong

Auto-generated profile, based on publicly available information

Minghan Yong

The University of Auckland Faculty of Medical and Health Sciences, Molecular Medicine and Pathology, Auckland, New Zealand

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
NHNuala Helsby
Nuala Helsby
MYMinghan Yong
Minghan Yong
KBKatie Burns
Katie Burns
MFMichael Findlay
Michael Findlay
DPDavid Porter
David Porter

8 September 2021 in Xenobiotica
Verified
Journal Article
Closed access
MYMinghan Yong
Minghan Yong
KBKatie Burns
Katie Burns
JZJanak de Zoysa
Janak de Zoysa
NHNuala Ann Helsby
Nuala Ann Helsby
The conversion of the cyclophosphamide intermediate metabolite 4-hydroxycyclophosphamide (4-OHCP) to the final cytotoxic metabolite phosphoramide mustard (PAM) is classically assumed to occur via chemical hydrolysis of the phospho-ester bond. Whilst it has been suggested previously that this reaction could be enzyme-catalysed, there was only indirect evidence for this (i.e. formation of the by-product acrolein). Using an assay to detect formation of DNA-alkylating adducts which block PCR amplification (QPCR-block assay), we have demonstrated that 4-OHCP can be activated by peripheral blood mononuclear cells (PBMC). The DNA-alkylating potency of 4-OHCP in PBMC increased >18-fold compared to the intrinsic reactivity of 4-OHCP for purified gDNA. We also found that immortalised T-cells (Jurkat) had a similar ability to activate 4-OHCP into a DNA alkylating agent, whereas there was no appreciable activation in epithelial derived (Caco-2) cells. This suggests the possibility of tissue-specific enzyme expression. Of the candidate enzymes tested only recombinant human cAMP-phosphodiesterase-PDE4B and snake-venom phosphodiesterase (PDE-I) could catalyse this activation into a DNA-alkylating agent. This enzymatic catalysis of the phospho-ester bond (P-O-C) is a hitherto unrecognised feature of this important immunomodulatory drug and should be investigated further.